Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women ...Middle East

-- Top-line readout of data expected in October 2022 -- -- U.S. regulatory submission planned for the first half of 2023 -- -- Phexxi may become the first-ever woman-controlled prophylactic for the prevention of chlamydia and gonorrhea -- SAN DIEGO, Aug. 1, 2022 /PRNewswire/ -- Evofem...

Hence then, the article about evofem announces completion of last subject last visit lslv in registrational phase 3 evoguard trial evaluating phexxi for the prevention of chlamydia and gonorrhea in women was published today ( Monday 01/08/2022 - 04:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women )

Also on site :

• Russia exposed plot to blow up Black Sea gas pipelines – Putin
• NATO nations could transfer nuclear bomb to Ukraine – Russian intelligence
• Peter Mandelson arrest latest: Peer released on bail as Epstein accuser Virginia Giuffre’s family issues statement